Compare Stocks → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:IFRXNASDAQ:NLTXNASDAQ:SESNNASDAQ:STSANASDAQ:TERN Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIFRXInflaRx$1.30-4.4%$1.54$1.14▼$5.20$76.54M1.27236,311 shs44,776 shsNLTXNeoleukin Therapeutics$30.23-3.0%$37.24$2.03▼$14.36$284.10M1.1150,104 shs52,572 shsSESNSesen Bio$10.50$0.37▼$12.58$2.56B0.831.07 million shs93,330 shsSTSASatsuma Pharmaceuticals$1.10-0.9%$1.08$0.59▼$8.08$36.47M0.1701,788 shs1.83 million shsTERNTerns Pharmaceuticals$4.55-4.2%$6.51$3.26▼$13.51$294.16M-0.63851,856 shs161,240 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIFRXInflaRx0.00%+7.51%-11.69%-9.33%-71.06%NLTXNeoleukin Therapeutics0.00%-11.45%-36.43%+3.90%+84.46%SESNSesen Bio0.00%0.00%0.00%0.00%0.00%STSASatsuma Pharmaceuticals0.00%0.00%0.00%0.00%+4.76%TERNTerns Pharmaceuticals+1.28%+4.63%-26.01%-10.55%-62.09%Mysterious Gold Leverage Just Announced (Ad)World's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.Find out what it is and see how you can get in with just a few dollars.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIFRXInflaRx2.2002 of 5 stars3.83.00.00.00.01.71.3NLTXNeoleukin TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ASESNSesen BioN/AN/AN/AN/AN/AN/AN/AN/ASTSASatsuma PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ATERNTerns Pharmaceuticals3.5913 of 5 stars3.41.00.04.12.03.30.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIFRXInflaRx3.50Strong Buy$13.50938.46% UpsideNLTXNeoleukin TherapeuticsN/AN/A$30.00-0.76% DownsideSESNSesen BioN/AN/AN/AN/ASTSASatsuma PharmaceuticalsN/AN/AN/AN/ATERNTerns Pharmaceuticals2.75Moderate Buy$14.94228.30% UpsideCurrent Analyst RatingsLatest STSA, NLTX, SESN, IFRX, and TERN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/27/2024TERNTerns PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$19.00 ➝ $18.003/22/2024IFRXInflaRxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.003/18/2024TERNTerns PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$17.00 ➝ $15.003/15/2024TERNTerns PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$5.503/15/2024TERNTerns PharmaceuticalsBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$18.00 ➝ $19.001/25/2024IFRXInflaRxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$9.00 ➝ $8.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIFRXInflaRx$70K1,093.49N/AN/A$1.89 per share0.69NLTXNeoleukin TherapeuticsN/AN/AN/AN/A$11.08 per shareN/ASESNSesen Bio$40M0.00N/A3.39$0.78 per share0.00STSASatsuma PharmaceuticalsN/AN/AN/AN/A$1.41 per shareN/ATERNTerns Pharmaceuticals$1M294.16N/AN/A$4.13 per share1.10Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIFRXInflaRx-$46.18M-$0.86N/AN/AN/AN/A-40.10%-36.24%5/9/2024 (Estimated)NLTXNeoleukin Therapeutics-$57.56M-$3.11N/A∞N/AN/A-37.22%-30.91%N/ASESNSesen Bio-$19.88M-$0.10N/AN/AN/AN/A6.70%5.41%N/ASTSASatsuma Pharmaceuticals-$70.06M-$2.01N/AN/AN/AN/A-115.24%-102.26%N/ATERNTerns Pharmaceuticals-$90.21M-$1.27N/AN/AN/AN/A-33.55%-31.90%5/20/2024 (Estimated)Latest STSA, NLTX, SESN, IFRX, and TERN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/21/2024Q4 2023IFRXInflaRx-$0.20-$0.30-$0.10-$0.30N/AN/A3/14/2024Q4 2023TERNTerns Pharmaceuticals-$0.29-$0.29N/A-$0.29N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIFRXInflaRxN/AN/AN/AN/AN/ANLTXNeoleukin TherapeuticsN/AN/AN/AN/AN/ASESNSesen BioN/AN/AN/AN/AN/ASTSASatsuma PharmaceuticalsN/AN/AN/AN/AN/ATERNTerns PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIFRXInflaRxN/A6.505.82NLTXNeoleukin TherapeuticsN/A15.3315.33SESNSesen BioN/A6.106.10STSASatsuma PharmaceuticalsN/A7.447.44TERNTerns PharmaceuticalsN/A22.3922.39OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIFRXInflaRx42.39%NLTXNeoleukin Therapeutics52.37%SESNSesen Bio16.45%STSASatsuma Pharmaceuticals93.26%TERNTerns Pharmaceuticals98.26%Insider OwnershipCompanyInsider OwnershipIFRXInflaRx16.30%NLTXNeoleukin Therapeutics1.58%SESNSesen Bio3.20%STSASatsuma Pharmaceuticals31.20%TERNTerns Pharmaceuticals17.40%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableIFRXInflaRx6258.88 million49.29 millionOptionableNLTXNeoleukin Therapeutics79.40 million9.25 millionOptionableSESNSesen Bio35203.49 million196.98 millionOptionableSTSASatsuma Pharmaceuticals2133.15 million22.81 millionNot OptionableTERNTerns Pharmaceuticals6664.65 million53.40 millionNot OptionableSTSA, NLTX, SESN, IFRX, and TERN HeadlinesSourceHeadlineTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Given Average Recommendation of "Moderate Buy" by Analystsamericanbankingnews.com - April 25 at 1:22 AMTerns Pharmaceuticals Inc Ordinary Sharesmorningstar.com - April 18 at 6:23 PMIntra-Cellular depression data has investors feeling goodthepharmaletter.com - April 17 at 3:21 PMKumquat Biosciences joins forces with Takeda on I-O developmentthepharmaletter.com - April 17 at 3:21 PMTerns Pharmaceuticals, Inc.: Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officerfinanznachrichten.de - April 11 at 8:35 AMTerns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officerglobenewswire.com - April 10 at 4:05 PMMadrigal announces US launch of NASH/MASH drug Rezdifframsn.com - April 9 at 10:28 AMVivo Capital entities sell Terns Pharmaceuticals shares worth $2.8 millioninvesting.com - April 5 at 10:17 AMVivo Opportunity, Llc Sells 138,066 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Stockinsidertrades.com - April 5 at 5:24 AMTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Major Shareholder Vivo Opportunity, Llc Sells 181,117 Sharesinsidertrades.com - April 4 at 6:15 AMThis small-cap stock is expected to take off - if its weight-loss pill trial succeedsmorningstar.com - March 30 at 7:03 PMThis small-cap stock is expected to take off — if its weight-loss pill trial succeedsmarketwatch.com - March 28 at 3:24 PMUBS Group Lowers Terns Pharmaceuticals (NASDAQ:TERN) Price Target to $18.00marketbeat.com - March 27 at 3:09 PMHere’s Why Ozempic And Mounjaro Rivals Won’t Topple Weight Loss Drugmakers Novo Nordisk And Eli Lilly Anytime Soonmsn.com - March 27 at 9:31 AMWall Street's Favorite Biotech Stocks? 3 Names That Could Make You Filthy Richinvestorplace.com - March 25 at 3:00 PMOptimistic Buy Rating for Terns Pharmaceuticals Based on Strong Clinical Pipeline and Financial Stabilitymarkets.businessinsider.com - March 21 at 6:49 AMTERN Apr 2024 15.000 callfinance.yahoo.com - March 16 at 1:45 PMTerns Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updatesglobenewswire.com - March 14 at 4:05 PMTerns Pharmaceuticals, Inc.: Terns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid Leukemiafinanznachrichten.de - March 12 at 4:18 AMTerns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid Leukemiaglobenewswire.com - March 11 at 4:05 PMTerns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)globenewswire.com - March 7 at 4:05 PMTerns Pharmaceuticals to Participate in Upcoming March Investor Conferencesglobenewswire.com - February 27 at 4:05 PMTerns Pharmaceuticals, Inc.: Terns Pharmaceuticals Reports Inducement Grants to New Chief Executive Officer Under Nasdaq Listing Rule 5635(C)(4)finanznachrichten.de - February 9 at 9:57 AMTerns Pharmaceuticals, Inc.: Terns Pharmaceuticals Appoints Amy Burroughs as Chief Executive Officerfinanznachrichten.de - February 7 at 5:40 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsInflaRxNASDAQ:IFRXInflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.Neoleukin TherapeuticsNASDAQ:NLTXNeoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.Sesen BioNASDAQ:SESNSesen Bio, Inc. engages in designing, engineering, and developing targeted protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA.Satsuma PharmaceuticalsNASDAQ:STSASatsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.Terns PharmaceuticalsNASDAQ:TERNTerns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.